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Abstract
PURPOSE: To investigate whether TP53 mutation, 1p/19q codeletions, MGMT promoter methylation,
and IDH1 mutation predict natural course of disease or response to radiotherapy or chemotherapy, or
both, in low-grade glioma patients.EXPERIMENTAL DESIGN: Cohort A consisted of 89 patients with
diffuse astrocytoma WHO grade II (n=40), oligoastrocytoma (n=23) or oligodendroglioma (n=26), who
did not receive radiotherapy or chemotherapy after first operation and were monitored until progression
(PD) (n=59) and beyond or until the end of follow-up (n=30). Cohort B consisted of 50 patients with
WHO grade II gliomas who received radiotherapy or chemotherapy at diagnosis. Tumors were analysed
for TP53 mutations, 1p/19q codeletions, MGMT promoter methylation, and IDH1 mutations.RESULTS:
Median progression-free survival (PFS) in cohort A was 4.1 years (95% CI 3.1-5.1). No molecular
marker was prognostic for PFS after surgery alone using multivariate adjustment for histology, age and
extent of resection. IDH1 mutations were associated with prolonged survival from the diagnosis of PD
in OA II/O II and with overall survival (OS) in all tumors. 1p/19q codeletion and IDH1 mutation were
prognostic for PFS and OS in cohort B.CONCLUSIONS: Neither parameter is a sensitive prognostic
biomarker in WHO grade II glioma patients who do not receive radiotherapy or chemotherapy after
surgery. Limitations of this study include the selection of patients with favourable outcome, the
non-randomized allocation of treatment, and the insufficient sample size to distinguish between effects
of radiotherapy versus chemotherapy. Regardless of histology, IDH1 mutation status is the strongest
prognostic marker for OS.
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Abstract 
 
PURPOSE: To investigate whether TP53 mutation, 1p/19q codeletions, MGMT 
promoter methylation, and IDH1 mutation predict natural course of disease or 
response to radiotherapy or chemotherapy, or both, in low-grade glioma patients. 
EXPERIMENTAL DESIGN: Cohort A consisted of 89 patients with diffuse 
astrocytoma WHO grade II (n=40), oligoastrocytoma (n=23) or oligodendroglioma 
(n=26), who did not receive radiotherapy or chemotherapy after first operation and 
were monitored until progression (PD) (n=59) and beyond or until the end of follow-
up (n=30). Cohort B consisted of 50 patients with WHO grade II gliomas who 
received radiotherapy or chemotherapy at diagnosis. Tumors were analysed for TP53 
mutations, 1p/19q codeletions, MGMT promoter methylation, and IDH1 mutations. 
RESULTS: Median progression-free survival (PFS) in cohort A was 4.1 years (95% 
CI 3.1-5.1). No molecular marker was prognostic for PFS after surgery alone using 
multivariate adjustment for histology, age and extent of resection. IDH1 mutations 
were associated with prolonged survival from the diagnosis of PD in OA II/O II and 
with overall survival (OS) in all tumors. 1p/19q codeletion and IDH1 mutation were 
prognostic for PFS and OS in cohort B. 
CONCLUSIONS: Neither parameter is a sensitive prognostic biomarker in WHO 
grade II glioma patients who do not receive radiotherapy or chemotherapy after 
surgery. Limitations of this study include the selection of patients with favourable 
outcome, the non-randomized allocation of treatment, and the insufficient sample 
size to distinguish between effects of radiotherapy versus chemotherapy. Regardless 
of histology, IDH1 mutation status is the strongest prognostic marker for OS. 
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Introduction 
 
Several molecular markers have been proposed as potential predictors of outcome in 
patients with World Health Organization (WHO) grade II gliomas, which comprise 
diffuse astrocytomas (A II), mixed oligoastrocytomas (OA II) and oligodendrogliomas 
(O II). The outcome has traditionally been considered to be more favorable in O II 
and less favorable in A II whereas OA II has been attributed an intermediate 
prognosis (1, 2). Some molecular aberrations are linked to histological subtypes of 
WHO grade II gliomas and may therefore be of diagnostic value, e.g., TP53 
mutations are more common in A II whereas combined deletions of 1p and 19q 
(1p/19q deletion) are more common in OA II and O II. 
The clinical relevance of these molecular changes has remained controversial. Thus, 
is has remained unclear whether it is the 1p/19q deletion or the oligodendroglial 
morphology that confers a less aggressive course of disease compared with A II. 
Moreover, within one histological subtype of WHO grade II glioma, the clinical 
relevance of the molecular markers has remained controversial. Finally, it has proven 
difficult to distinguish prognostic significance, defined as overall better outcome 
irrespective of management, from predictive significance, defined as a better 
outcome provided a specific treatment is administered. 
For instance, 1p/19q deletion resulting from an unbalanced translocation (3, 4) 
preferentially in oligodendroglial tumors were first associated with sensitivity to 
alkylating agent chemotherapy (5) and later to sensitivity to radiotherapy as well (6). 
Eventually, we reported that the 1p/19q deletion loses its powerful prognostic impact 
if patients (with WHO grade II gliomas) receive no further radiotherapy or 
chemotherapy after surgery (7), making the 1p/19q deletion a candidate predictive 
marker for prolonged progression-free survival (PFS) and overall survival (OS) in 
 4
response to DNA-damaging treatments in general. Yet, neuroradiological monitoring 
nevertheless revealed a slower spontaneous growth rate in untreated 1p/19q-deleted 
low-grade gliomas than in untreated 1p/19q-non-deleted tumors (8). 
In contrast, the prognostic or predictive role for TP53 mutations has remained 
controversial, and no consistent association with response to therapy or overall 
outcome has been reported (9-12). Similarly, in contrast to the strong predictive and 
prognostic role for methylation of the promoter region of the O6-
methylguanylmethyltransferase (MGMT) gene in newly diagnosed glioblastoma 
patients treated with temozolomide, no such role has been defined in other gliomas 
(13). MGMT promoter methylation predicted a favorable outcome in WHO grade III 
anaplastic gliomas treated with either alkylating agent chemotherapy or radiotherapy 
(14, 15), and its significance in WHO grade II gliomas remains unclear (16). 
The identification of isocitrate dehydrogenase (IDH) 1 mutations in a minority of 
glioblastomas and pilocytic astrocytomas, but in the majority of WHO grade II and III 
gliomas (17-20) has dramatically altered our concepts of the origin and malignant 
progression of gliomas. In particular, it has become clear that most glioblastomas do 
not evolve from clinically silent low-grade gliomas; second, IDH1 mutations have 
been confirmed as early mutations in low grade gliomas (21), which may facilitate 
gliomagenesis along different morphological and molecular pathways, including 
astrocytoma more associated with TP53 mutations and oligodendroglioma more 
associated with 1p/19q deletion. Moreover, IDH1 mutations are associated with 
younger age and better outcome within each glioma entity (22-25). 
Here, we sought to evaluate the prognostic versus predictive relevance of molecular 
markers in WHO grade II gliomas and studied the four most prominent molecular 
markers thought to be involved in the development and progression or both of 
gliomas, TP53 mutation, 1p/19q deletion, MGMT promoter methylation, and IDH1 
 5
mutation, in the tumor tissue of patients who received neither radiotherapy nor 
chemotherapy after first surgery (cohort A). We asked whether the status of these 
markers correlated with the time to the diagnosis of progressive disease (PD) and/or 
the first therapeutic re-intervention, or with the survival from that re-intervention. 
Results in cohort A were compared with findings in a second set of patients (cohort 
B) who received radiotherapy or chemotherapy immediately after the first surgical 
intervention. 
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Materials and Methods 
 
Patient selection 
The centers of the German Glioma Network (GGN) identified 89 patients with A II 
(n=40), OA II (n=23) or O II (n=26) operated on from 1991 to 2006 who had not 
received radiotherapy or chemotherapy after their first operation (cohort A). These 
patients were monitored until the end of follow-up or until therapeutic re-intervention, 
which was based on the local diagnosis of progressive disease (PD) documented by 
neuroradiological criteria that conformed to Macdonald criteria (26) for contrast-
enhancing lesions or similar adapted criteria for non-enhancing lesions, and beyond. 
For comparison and possible validation, we studied a second group of 50 patients 
with A II (n=38), OA II (n=7) or O II (n=5) who were operated on from 1991 to 2009 
and were treated with radiotherapy alone (n=25), chemotherapy with alkylating 
agents alone (n=21) or radiotherapy and alkylating agents (n=4) immediately after 
the establishment of the diagnosis (cohort B). Individual data for both cohorts are 
provided in Supplementary Table 1. 
 
Central reference pathology 
Formalin-fixed, paraffin-embedded material was submitted from the local 
(neuro)pathologists of the GGN centers for an independent histopathological review 
to the Brain Tumor Reference Center of the German Society of Neuropathology and 
Neuroanatomy in Bonn. All tumors were classified according to the WHO 
classification of tumors of the central nervous system (27). In case of differences 
between local and central reference diagnosis, the reference diagnosis overruled the 
local diagnosis for data analysis. 
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Molecular studies 
Prior to the extraction of DNA from tumor tissues by standard methods, all tumor 
samples were examined by two experienced neuropathologists (CH, AvD) to assure 
an estimated tumor cell content of 80% or more. The techniques to determine TP53 
mutations by single strand confirmation polymorphism (SSCP) analysis followed by 
direct sequencing (28), MGMT promoter methylation by one stage methylation-
specific-PCR (MS-PCR) (29) (detection of a band on agarose gel in the lane 
containing PCR products generated by methylation-specific primers was scored as 
positive), IDH1 or IDH2 mutations by direct sequencing (30) and 1p/19q deletion by 
multiplex ligation-dependent probe amplification (MLPA) (7) have all been described 
elsewhere. Cohort B patients were not analyzed for IDH2 mutations. If formalin-fixed 
and paraffin-embedded tissue was available, fluorescence in situ hybridization (FISH) 
was alternatively applied to determine 1p/19q deletion. The two-color FISH assay 
was done on 5 µm-thick sections using mixed 1p36/1q25 and 19p13/19q13 dual 
color probe sets (Cat. No 32-231004, Vysis, Inc., Applied Biosystems, Downers 
Grove, IL). For slide pretreatment, probe hybridization and posthybridization 
processing, the Histology Accessory FISH Kit (Dakopatts, Glostrup, DK) was applied. 
Samples showing sufficient FISH efficiency (~90% nuclei with signals) were 
evaluated. Signals were scored in at least 200 non-overlapping, intact nuclei. 
Deletions of 1p and 19q were defined as 50% of tumor nuclei containing one signal 
(31). 
 
Statistical analysis 
The association of clinical data and molecular markers were analyzed by Chi2-test 
and Fisher’s exact test. Because of the descriptive manner of these analyses, p-
values were not adjusted for multiple testing. PFS, OS and survival from the first re-
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intervention in cohort A were analyzed by log rank test. PFS was calculated from the 
day of first surgery until tumor progression, death or end of follow up. OS was 
calculated from the day of first surgery until death or end of follow up. Survival from 
first re-intervention in cohort A was calculated from the diagnosis of PD until death or 
end of follow up. Cox regression models were fitted to assess the independent 
impact of the molecular markers adjusting for age (>40 versus <=40), diagnosis (aII 
versus pooled OA II and O II), extent of resection (total versus not-total). KPS was 
not included for too many missing values. Data were analyzed by PASW Statistics 18 
(Version 18.0.0). 
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Results 
 
Cohort A consisted of 60 males and 29 females. The median follow-up was 6.3 
years. PD was diagnosed in 59 patients and 17 patients have died. The estimated 
median PFS without radiotherapy or chemotherapy was 4.1 years (95% CI 3.1-5.1). 
The median follow-up was 8.6 years for A II, 5.5 for OA II and 6.1 for O II. PD was 
documented in 75.0% of A II patients (30/40), 65.2% of OA II patients (15/23) and 
53.8% of O II patients (14/26). After diagnosis of PD, five patients had second 
surgery, 8 patients received radiotherapy alone, 25 patients received radiotherapy 
and alkylating agents, and 9 patients alkylating agents alone; four patients died 
shortly after PD, four patients had follow-up of less than 3 months after PD, and four 
had no further treatment at a follow-up of 1.5 to 8.5 years. The median OS was 15.5 
years for all patients, 17.8 years for pooled OA II and O II, and undetermined for A II 
because the probability of OS was > 50% (Supplementary Figure 1). 
Cohort B consisted of 29 males and 21 females. The median follow-up was 3.8 
years. The initial treatment was radiotherapy alone in 25 patients, alkylating agent 
chemotherapy alone in 21 patients, and combined radiochemotherapy in 4 patients. 
PD was documented in 22 patients and 8 patients died. The estimated median PFS 
with initial treatment was 6.1 years (95% CI 2.1-10.1). The median follow-up was 3.1 
years for A II patients and 4.4 years for patients with OA II or O II. PD was 
documented in 50% of A II patients (19/38), and 25% of OA II or O II patients (3/12). 
The median OS was 13.6 years for all patients, 8.1 years for A II patients and 13.6 
years for OA II or O II patients. 
 
Molecular data 
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The demographic data and clinical features pooled by histology for cohort A patients 
and by molecular marker status are summarized in Table 1. Three patients with IDH1 
mutations did not have the classical R132H mutations: we found three R132C 
mutations, two in OA II and one in A II. Only one patient with OA II in cohort A had an 
IDH2 mutation. He was analyzed within the group of patients with IDH1 mutant 
tumors. Patients with TP53 and IDH1 mutations were younger than patients without 
TP53 mutations. The other molecular markers were not linked to age. No molecular 
marker was linked to gender. Oligodendroglial histology was associated with 1p/19q 
deletion and less so with MGMT promoter methylation whereas A II was associated 
with TP53 mutation. Patients with TP53 mutant tumors had more aggressive surgery 
than patients withTP53 wild-type tumors, an observation that is difficult to explain. 
Supplementary Table 2 shows these data for cohort B. The trends were similar as in 
cohort A, with lower significance, presumably because of lower patient numbers, 
except for the association of the 1p/19q deletion with OA II and O II. 
All four molecular markers were informative in 81 of 89 cohort A patients. Table 2 
shows the interrelations between specific molecular markers. None of four alterations 
were found in 7 patients, 5 A II and two OA II patients. IDH1 wild-type tumors were 
found in 15 patients: 9 A II, four OA II, two O II. Only one OA II patient had both TP53 
mutation and 1p/19q deletion. A similar pattern based on larger subgroups emerged 
when cohorts A and B and OA II and O II were pooled (Supplementary Table 3). 
Compared with IDH wild-type tumors, IDH mutant tumors had more often 1p/19q 
codeletions (43.5% versus 26.9%, p=0.13) as well more often p53 mutations (29.4% 
versus 15.4%, p=0.154) and MGMT promoter methylation status (47.1% versus 
30.8%, p=0.142). None of these associations reached statistical significance. 
 
Survival analyses 
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Figure 1 and Table 3A show PFS of cohort A patients by histology and molecular 
markers. None of the molecular markers was prognostic for PFS for all tumors pooled 
or for single histological entities. There were interesting trends for prolonged PFS in 
O II and OA II favoring the absence of MGMT promoter methylation, but not the 
presence of 1p/19q deletion, and for prolonged PFS with IDH1 mutations in A II. 
Table 3B shows that IDH1 mutations were associated with longer survival from first 
PD or re-intervention in the pooled group of patients with OA II or O II. Moreover, 
there was a trend for better survival with 1p/19q deletion in the entire cohort A and 
specifically in OA II/O II patients. Finally, the unfavorable trend of MGMT promoter 
methylation persisted. Sample sizes became too small to allow estimates on the role 
of specific treatments administered at re-intervention. 
We also analysed OS from the initial diagnosis as summarized in Table 3C. Given 
the natural course of WHO grade II gliomas, the number of events is still small. 
However, IDH1 mutation emerged as the most powerful parameter of outcome when 
comparing 5-year survival rates. 
For comparison and possible validation of the observations in cohort A patients 
summarized in Tables 3B and 3C, we also analyzed PFS and OS in cohort B patients 
who were not observed after the first surgical intervention, but treated with 
radiotherapy or chemotherapy or both. Like in cohort A (Table 3B), both 1p/19q 
deletion and IDH1 mutation were associated with longer PFS in response to 
intervention (Table 4A). Furthermore, 1p/19q deletion and IDH1 mutation were 
associated with longer OS (Table 4B). Again, sample sizes were too small to 
compare specific treatments. 
 
Multivariate analyses 
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An overall analysis of the distribution of molecular changes and outcomes in our 
pooled sample of cohorts A and B allowed the distinction of three groups of patients: 
patients with IDH1 mutation and 1p/19q deletion, the majority of which had OA II or O 
II, patients with IDH1 mutation, but no 1p/19q deletion, the majority of which had A II, 
and patients without IDH1 mutation whose tumors corresponded to different 
histologies and who share a less favorable outcome (Fig. 2A-C). 
Several models were built to assess prognostic factors for the time to PD or re-
intervention or both in cohort A. Each molecular marker was analyzed in separate 
models adjusted for age, diagnosis and extent of resection. No molecular marker, not 
even IDH1 mutation, showed a significant interrelation with time to PD or re-
intervention (Fig. 2D). In further separate models for each molecular marker, OS was 
also analyzed in cohort A (Fig. 2E). 
Based on the observed three groups of the combination of IDH1 mutation and 1p/19q 
status, an indicator variable was built and analyzed in further multivariate models for 
time to PD or re-intervention (Table 5A), survival from first PD or re-intervention 
(Table 5B), and OS (Table 5C) in cohort A. Multivariate analyses for cohort B are 
summarized in Supplementary Table 4. Cohort A patients with IDH1 mutation and 
1p/19q codeletion were considered as the reference group. Age and extent of 
resection were included in the model, as well therapy after PD (yes versus no) for the 
analysis of survival from first PD or re-intervention. Age > 40 years was associated 
with a relevant increased risk for death regarding survival from first PD or re-
intervention (RR=2.5, p=0.155) and OS (RR=2.5, p=0.147), but was not associated 
with time to PD (RR=1.0, p=0.891). Total resection showed a strong positive effect on 
survival from first PD or re-intervention (RR=0.4, p=0.163) and OS (RR=0.3, 
p=0.090), and there was a positive trend for total resection and time to PD, too. 
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Radiotherapy and/or chemotherapy at PD was associated with a decreased risk of 
death (RR=0.4, p=0.217). 
The risk for PD was doubled (RR=2.1, p=0.067) for IDH1 wild-type status compared 
with IDH1 mutant status and 1p/19q codeletion, and increased moderately to 1.4 
(p=0.362) for IDH1 mutant status and no 1p/19q codeletion. Compared with the 
reference category (IDH1 mutant and 1p/19q codeletion), IDH1 wild-type had the 
strongest effect on survival from PD or re-intervention (RR=3.0, p=0.183), followed by 
IDH1 mutant, but no 1p/19q codeletion (RR=1.4, p=0.694). Similar results were 
observed for analyses of OS. The risk of death strongly increased in relation to IDH1 
mutation and 1p/19q codeletion for IDH1 wild-type (RR=4.1, p=0.081), and only 
moderately for IDH1 mutation and no 1p/19q codeletion (RR=1.4, p=0.648). 
In the pooled cohorts A + B, each molecular marker was also analyzed with 
adjustment for age, diagnosis, extent of resection and adjuvant therapy after first 
surgery (yes versus no). MGMT, 1p/19q codeletion and TP53 each showed a non-
significant association with OS. Only IDH1 mutations were significantly associated 
with OS (RR=0.3, p=0.022) (Fig. 2F). Analysis of OS including the combination of 
IDH1 and 1p/19q status as indicator variables and adjusted for age and extent of 
resection showed a strong effect of IDH1 wild-type status compared with IDH1 
mutation and 1p/19q codeletion (RR=8.0, p=0.004). For the comparison of IDH1 
mutation, but no 1p/19q codeletion, with IDH1 mutation and 1p/19q codeletion, an 
increased risk of 2.3 (p=0.260) was observed (data not shown). 
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Discussion 
 
The number of clinical, histopathological and molecular prognostic markers to 
estimate the outcome of patients with various types of gliomas, including low grade 
gliomas, is steadily increasing (2, 32). In contrast, few studies have tried to 
distinguish markers that characterize the natural course of disease from markers that 
predict PFS and OS in response to specific therapeutic measures. The observation 
until first PD of surgically treated patients followed without adjuvant radiotherapy or 
chemotherapy is the only way to determine whether a marker predicts outcome in the 
absence of adjuvant DNA-damaging treatment and is thus a prognostic marker 
independent of radiotherapy and chemotherapy. For instance, 1p/19q deletion is 
strongly predictive for prolonged PFS and OS in patients with anaplastic 
oligodendroglial tumors (WHO grade III) who are treated with radiotherapy or 
radiotherapy plus nitrosourea-based chemotherapy or temozolomide alone (14, 33, 
34). Yet, 1p/19q deletion did not predict PFS in patients, mostly with WHO grade II 
oligodendroglial tumors, who were treated by surgery alone (7), suggesting a link 
between this molecular marker and response to genotoxic therapies. 
We here extend this observation and report that neither TP53 mutation, 1p/19q 
deletion, MGMT promoter methylation nor IDH1 mutation are sensitive prognostic 
markers for PFS in patients with WHO grade II gliomas treated with surgery alone 
(Table 3A, Figure 1). In contrast, 1p/19q deletion and IDH1 mutation assumed 
prognostic relevance after re-intervention in cohort A (Table 3B,C) and were 
prognostic for PFS in cohort B patients who were treated with radiotherapy, 
chemotherapy or both already at diagnosis (Table 4). 
IDH1 mutations have previously been linked to improved OS, but not response to 
temozolomide at progression after radiotherapy, in patients with low grade 
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astrocytomas in a Dutch study (35) whereas a French study observed better 
response to temozolomide and better OS in patients with IDH1 mutant tumors (24). 
We find that IDH1 mutant A II may have a less aggressive spontaneous behaviour 
and observed that the differential outcome of IDH1 mutant versus IDH1 wild-type 
tumors becomes much more visible once tumor-specific treatment has been initiated 
(Tables 3B,C, Table 4, Table 5, Supplementary Figure 1). Moreover, we confirm that 
IDH1 wild-type low-grade gliomas can be viewed as a distinct prognostic entity with 
inferior outcome (25). In contrast, the prognostic role of IDH1 mutation in low-grade 
glioma patients has not been confirmed in all series. In fact, the largest series 
published so far reported two unexpected findings, first, an association of IDH1 
mutations with older age as well as a lack of correlation with outcome (36). 
The unexpected suggestion of possibly shortened PFS in patients with WHO grade II 
oligodendroglial tumors with MGMT promoter methylation (Table 3A) has a precedent 
in that a similar observation was made in a small cohort of diffuse astrocytoma 
patients from Japan (16), and is unexpected in view of the favorable prognostic role 
of MGMT promoter methylation in WHO grade III and IV gliomas (13). 
We acknowledge that our study has weaknesses. The sample size for each entity is 
small, the design is in part retrospective, and choice of treatment was not 
standardized. There was no central neuroradiological review to confirm PD, but there 
were also no standardized criteria to monitor disease progression in these tumors 
until recently (37). Cohort A is a selected group of patients with low grade gliomas 
because the treating physicians considered observation after surgery a reasonable 
strategy, but we tried to compensate for that by including a cohort B for comparison. 
Yet, this introduces a bias for the comparison of both groups because patients in 
cohort B were considered by their physicians to require adjuvant radiotherapy or 
chemotherapy after surgery. On the other hand, OS was long and comparable in both 
 16
cohorts, indicating that the extent of bias between both cohorts is limited, but that 
both cohorts represent favourable groups of patients with low-grade gliomas. 
Tables 2 and Supplementary Table 3 illustrate the likely molecular pathogenesis of 
low grade gliomas. IDH1 mutations are early and therefore presumably important 
lesions. They give rise to the formation of oligodendroglial tumors in the face of 
1p/19q codeletions and otherwise lead to A II. IDH1 wild-type tumors are less well 
understood and share a less favourable prognosis, irrespective of histology (Table 5). 
Yet, our data indicate that none of the biomarkers studied here is a sensitive 
predictor of PFS for glioma patients in the absence of genotoxic treatment whereas 
the profound impact of IDH1 mutations on OS was confirmed. In that regard, our 
study may provide so far the strongest evidence for differential responsiveness to 
genotoxic therapy of IDH1 mutant versus IDH1 wild-type low grade gliomas. 
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Figure legends 
 
Figure 1. PFS in cohort A by histology and molecular markers. A, AII versus OA 
II versus O II, B, age > 40 versus < 40; C, total versus no total resection; D-F, PFS by 
TP53 mutation in A II, OA II/O II and all tumors; G-I, PFS by 1p/19q deletion in A II, 
OA II/O II and all tumors; J-L, PFS by MGMT promoter methylation in A II, OA II/O II 
and all tumors; M-O, PFS by IDH1 mutations in A II, OA II/O II and all tumors. 
 
Figure 2. Multivariate analysis of outcome. PFS (A) and OS (B) in cohort A and 
OS (C) in pooled cohorts A+B in three low grade glioma groups defined by IDH1 
mutation and 1p/19 codeletion status. D-F, Forest plots for the corresponding three 
analyses of A-C. 
 
Supplementary Figure. OS in cohort A by histology and molecular markers. A, 
A II versus OA II versus O II, B, age > 40 versus < 40; C, total versus no total 
resection; D-F, OS by TP53 mutation in A II, OA II/O II and all tumors; G-I, OS by 
1p/19q deletion in A II, OA II/O II and all tumors; J-L, OS by MGMT promoter 
methylation in A II, OA II/O II and all tumors; M-O, OS by IDH1 mutations in A II, OA 
II/O II and all tumors. 
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Table 1. Molecular markers by age, gender, histology and extent of resection in cohort A 
 
 All TP53 mutation 
no TP53 
mutation 
p 
value 
1p/19q 
loss 
no 
1p/19q 
loss 
p 
value 
MGMT 
promoter 
methylati
on 
no MGMT 
promoter 
methylati
on 
p 
value 
IDH1 
mutation 
no 
IDH1 
mutation 
p 
value 
Age (years)    0.003   0.479   0.153   0.030 
< 40 
 
> 40 
 
 
 
 
Median 
(range) 
54 
(60.7%) 
35 
(39.3%) 
 
89 (100%) 
 
36.7 
(17.4-75.7) 
21 
(87.5%) 
3 
(12.5%) 
 
24 (100%) 
 
33.3 
(21.1-51.2) 
33 
(52.4%) 
30 
(47.6%) 
 
63 (100%) 
 
39.8 
(17.4-75.0) 
 20 
(57.1%) 
15 
(42.9%) 
 
35 (100%) 
 
36.2 
(17.4-66.9) 
33 
(64.7%) 
18 
(35.3%) 
 
51 (100%) 
 
36.7 
(19.1-75.7) 
 19 
(51.4%) 
18 
(48.6%) 
 
37 (100%) 
 
39.4 
(19.1-65.1) 
32 
(66.7%) 
16 
(33.3%) 
 
48 (100%) 
 
36.95 
(17.4-75.0) 
 48 
(66.7%) 
24 
(33.3%) 
 
72 (100%) 
 
35.55 
(17.4-75.0) 
6 
(37.5%) 
10 
(62.5%) 
 
16 (100%) 
 
43.7 
(25.3-74.0) 
 
Gender    0.448   0.109   0.243   1.000 
Male 60 
(67.4%) 
18 
(75.0%) 
41 
(65.1%) 
 20 
(57.1%) 
38 
(74.5%) 
 28 
(75.7%) 
30 
(62.5%) 
 48 
(66.7%) 
11 
(68.8%) 
 
Female 29 
(32.6%) 
 
6 
(25.0%) 
22 
(34.9%) 
 15 
(42.9%) 
13 
(25.5%) 
 9 
(24.3%) 
18 
(37.5%) 
 24 
(33.3%) 
5 
(31.3%) 
 
 89 (100%) 
 
24 (100%) 63 (100%)  35 (100%) 51 (100%)  37 (100%) 48 (100%)  72 (100%) 16 (100%)  
Histological 
diagnosis 
   0.032   <0.0001   0.031   0.186 
A II 40 
(44.9%) 
16 
(66.7%) 
23 
(36.5%) 
 5 
(14.3%) 
32 
(62.7%) 
 11 
(29.7%) 
27 
(56.3%) 
 29 
(40.3%) 
10 
(62.5%) 
 
O AII 23 
(25.8%) 
5 
(20.8%) 
18 
(28.6%) 
 12 
(34.3%) 
11 
(21.6%) 
 14 
(37.8%) 
8 
(16.7%) 
 19 
(26.4%) 
4 
(25.0%) 
 
O II 26 
(29.2%) 
3 
(12.5%) 
22 
(34.9%) 
 18 
(51.4%) 
8 
(15.7%) 
 12 
(32.4%) 
13 
(27.1%) 
 24 
(33.3%) 
2 
(12.5%) 
 
 2
 
 89 (100%) 24 (100%) 63 (100%)  35 (100%) 51 (100%)  37 (100%) 50 (100%)  72 (100%) 16 (100%)  
Extent of 
resection 
   0.013*   0.043*   0.574*   0.474* 
Biopsy only 8 
(9.0%) 
0 
(0.0%) 
7 
(11.1%) 
 3 
(8.6%) 
4 
(7.8%) 
 2 
(5.4%) 
5 
(10.4%) 
 5 
(6.9%) 
2 
(12.5%) 
 
Partial 
(<50%) 
10 
(11.2%) 
2 
(8.3%) 
8 
(12.7%) 
 5 
(14.3%) 
4 
(7.8%) 
 6 
(16.2%) 
4 
(8.3%) 
 7 
(9.7%) 
3 
(18.8%) 
 
Subtotal 
(50-99%) 
25 
(28.1%) 
3 
(12.5%) 
22 
(34.9%) 
 15 
(42.9%) 
10 
(19.6%) 
 11 
(29.7%) 
12 
(25.0%) 
 22 
(30.6%) 
3 
(18.8%) 
 
Total 38 
(42.7%) 
16 
(66.7%) 
21 
(33.3%) 
 10 
(28.6%) 
28 
(54.9%) 
 15 
(40.5%) 
22 
(45.8%) 
 31 
(43.1%) 
7 
(43.8%) 
 
not available 8 
(9.0%) 
 
3 
(12.5%) 
5 
(7.9%) 
 2 
(5.7%) 
5 
(9.8%) 
 3 
(8.1%) 
5 
(10.4%) 
 7 
(9.7%) 
1 
(6.3%) 
 
 89 (100%) 24 (100%) 63 (100%)  35 (100%) 51 (100%)  37 (100%) 48 (100%)  72 (100%) 16 (100%)  
 
Abbreviations: A II astrocytoma, OA II oligoastrocytoma, O II, oligodendroglioma; * p-values were calculated based on evaluable cases
Table 2. Patterns of molecular changes in cohort A WHO grade II gliomas by 
histology. 
 
 
Diagnosis  A II O AII O II 
All 
tumors 
5 2 0 7 No molecular marker altered 
14.3% 9.1% 0% 8.6% 
8 1 1 10 --------- / IDH1 / ------- / --------- 
22.9% 4.5% 4.2% 12.3% 
10 2 3 15 --------- / IDH1 / TP53 / --------- 
28.6% 9.1% 12.5% 18.5% 
1 1 0 2 --------- / ------- / ------- / MGMT  
2.9% 4.5% 0% 2.5% 
1 3 3 7 --------- / IDH1 / ------- / MGMT  
2.9% 13.6% 12.5% 8.6% 
1 0 0 1 --------- / ------- / TP53 / MGMT 
2.9% 0% 0% 1.2% 
4 2 0 6 --------- / IDH1 / TP53 / MGMT 
11.4% 9.1% 0% 7.4% 
1 0 2 3 1p/19q / ------- / ------- / ---------  
2.9% 0% 8.3% 3.7% 
1 3 7 11 1p/19q / IDH1 / ------- / --------- 
2.9% 13.6% 29.2% 13.6% 
1 1 0 2 1p/19q / ------- / ------- / MGMT  
2.9% 4.5% 0% 2.5% 
2 6 8 16 1p/19q / IDH1 / ------- / MGMT 
5.7% 27.3% 33.3% 19.8% 
0 1 0 1 1p/19q / IDH1 / TP53 / MGMT 
0% 4.5% 0% 1.2% 
All tumors 35 22 24 81 
 
 
 
Table 3. Survival analyses in cohort A. 
 
A. PFS with observation alone 
TP53 1p/19q MGMT IDH1  
P
a
t
i
e
n
t
s
 
(
n
)
 
E
v
e
n
t
s
 
(
n
)
 
 
Median 
PFS 
(95% CI) 
TP53 
mutation 
Median
PFS 
(years)
95% CI P value 
1p/19q 
loss 
Median
PFS 
(years)
95% CI P value 
MGMT 
promoter 
methylation 
Median 
PFS 
(years) 
95% CI P value
IDH1 
mutation 
Median 
PFS 
(years) 
95% CI P value 
A II 40 30 3.6 
(2.5-4.6) 
Yes (12/16) 
No (17/23) 
3.6 
3.6 
2.1-5.0 
1.0-.6.1 
0.373 Yes (2/5) 
No (26/32) 
- 
4.4 
- 
3.4-5.3 
0.171 Yes (7/11) 
No (21/27) 
4.6 
3.5 
2.6-6.6 
1.7-5.3 
0.199 Yes (21/29) 
No (8/10) 
4.3 
2.2 
2.6-6.0 
2.0-2.4 
0.067 
OA II 23 15 4.1 
(3.9-4.3) 
Yes (3/5) 
No (12/18) 
6.7 
4.1 
- 
3.1-5.1 
0.730 Yes (7/12) 
No (8/11) 
4.1 
4.1 
3.2-5.1 
1.0-7.3 
0.880 Yes (10/14) 
No (5/8) 
4.1 
6.7 
2.7-5.5 
1.3-12.1
0.943 Yes (12/19) 
No (3/4) 
4.1 
3.1 
0.4-7.9 
- 
0.310 
O II 26 14 5.1 
(1.9-8.2) 
Yes (1/3) 
No (12/22) 
- 
4.7 
- 
1.7-7.6 
0.061 Yes (10/18)
No (4/8) 
5.1 
12.9 
1.2-9.0 
- 
0.397 Yes (9/12) 
No (5/13) 
2.5 
12.9 
1.9-3.1 
- 
0.072 Yes (14/24) 
No (0/2) 
4.6 
- 
0.4-8.9 
- 
0.295 
OAII+OII 49 29 4.6 
(2.2-7.1) 
Yes (4/8) 
No (24/40) 
6.7 
4.1 
0.0-13.3
2.4-5.9 
0.201 Yes (17/30)
No (12/19) 
4.7 
6.7 
3.3-6.0 
0.9-12.5 
0.652 Yes (19/26) 
No (10/21) 
4.0 
6.7 
2.6-5.4 
3.4-9.9 
0.132 Yes (26/43) 
No (3/6) 
5.1 
4.0 
2.3-7.8 
2.0-6.0 
0.945 
All tumors 89 59 4.1 
3.1-5.1 
Yes (16/24) 
No (41/63) 
4.6 
4.1 
2.1-7.1 
2.9-5.3 
0.280 Yes (19/35)
No (38/51) 
4.7 
3.6 
3.4-5.9 
2.4-4.7 
0.350 Yes (26/37) 
No (31/48) 
4.1 
4.2 
2.4-5.8 
3.0-5.5 
0.947 Yes (47/72) 
No (11/16) 
4.5 
2.5 
4.0-5.1 
1.1-4.0 
0.127 
B. Survival from first PD or reintervention 
TP53 1p/19q MGMT IDH1  
P
a
t
i
e
n
t
s
 
(
n
)
 
E
v
e
n
t
s
 
(
n
)
 
 
Median 
survival 
(95% CI) 
TP53 
mutation 
Median
(years) 95% CI 
P 
value 
1p/19q 
loss 
Median 
(years) 95% CI 
P 
value 
MGMT 
promoter 
methylation 
Median 
(years) 95% CI
P 
value
IDH1 
mutation 
Median 
(years) 95% CI 
P 
value 
A II 30 10 8.9 
 (-) 
Yes (3/12) 
No  (6/17) 
8.9 
- 
- 
- 
0.358 Yes (1/2) 
No  (8/26) 
- 
8.9 
- 
- 
- Yes (1/7) 
No  (7/21) 
5.3 
- 
- 
- 
0.482 Yes (6/21) 
No  (3/8) 
- 
- 
- 
- 
0.276 
O AII 15 3 6.8 
 (1.9-11.8) 
Yes (1/3) 
No  (2/12) 
- 
6.8 
- 
0.0-15.2
0.150 Yes (0/7) 
No  (3/8) 
- 
- 
- 
- 
- Yes (1/10) 
No  (2/5) 
6.8 
- 
- 
- 
- Yes (2/12) 
No  (1/3) 
6.8 
- 
1.9-11.8 - 
O II 14 4 10.5 
 (2.2-18.8) 
Yes (1/1) 
No  (3/12) 
- 
10.5 
- 
- 
- Yes (3/10) 
No  (1/4) 
10.5 
- 
- 
- 
- Yes (2/9) 
No  (2/5) 
- 
- 
- 
- 
- Yes (4/14) 
No  (-) 
10.5 
- 
2.2-18.8 
- 
- 
OA II+O II 29 7 10.5 
(4.2-16.7) 
Yes (2/4) 
No  (5/24) 
3.4 
10.5 
- 
4.9-16.0
0.060 Yes (3/17) 
No  (4/12) 
10.5 
6.8 
1.9-19.1 
3.6-10.0 
0.334 Yes (3/19) 
No  (4/10) 
- 
4.9 
- 
1.9-8.0 
0.145 Yes (6/26) 
No  (1/3) 
10.5 
0.9 
3.3-17.6 
- 
0.024 
All tumors 59 17 10.5 
(5.1-15.8) 
Yes (5/16) 
No(11/41) 
8.9 
10.5 
1.8-15.9
2.8-18.2
0.945 Yes (4/19) 
No  (12/38) 
10.5 
8.6 
1.8-19.1 
3.3-14.4 
0.741 Yes (4/26) 
No  (11/31) 
6.8 
10.5 
- 
3.5-17.4
0.190 Yes (12/47) 
No  (4/11) 
10.5 
- 
5.1-15.9 
- 
0.058 
 
C. OS 
TP53 1p/19q MGMT  IDH1  
P
a
t
i
e
n
t
s
 
(
n
)
 
E
v
e
n
t
s
 
(
n
)
 
5-y. OS-rate 
(%) 
(95% CI) 
5-year 
OS rate 
(%) 
95% 
CI 
P TP53 mutation value 
1p/19q 
loss 
5-year 
OS rate 
(%) 
95% 
CI 
P 
value
MGMT 
promoter 
methylation 
5-year 
OS rate
(%) 
95% 
CI 
P 
value
IDH1 
mutation 
5-year 
OS rate 
(%) 
95% 
CI 
P 
value 
A II 40 10 84.7 
73.4-96 
Yes (3/16) 
No  (6/23) 
93.3 
82.6 
80.7-100
67.1-98.1
0.272 Yes (1/5) 
No  (8/32) 
80.0 
87.1 
44.9-100 
75.3-98.9 
0.701 Yes (1/11) 
No  (7/27) 
100.0 
  80.8 
- 
65.6-96 
0.338 Yes (6/29) 
No  (3/10) 
92.8 
70.0 
83.3-100 
41.6-98.4 
0.071 
OA II+O II 49 7 92.0 
83.3-100 
Yes (2/8) 
No  (5/40) 
83.3 
93.7 
53.5-100
85.2-100
0.702 Yes (3/30) 
No  (4/19) 
95.0 
87.8 
85.4-100 
72-100 
0.890 Yes (3/26) 
No  (4/21) 
  95.5 
  86.9 
86.8-100
69.8-100
0.788 Yes (6/43) 
No  (1/6) 
93.6 
80.0 
85.1-100 
44.9-100 
0.267 
All tumors 89 17 88.9 
81.9-95.8 
Yes (5/24) 
No  (11/63) 
90.5 
89.7 
77.9-100
81.8-97.5
0.499 Yes (4/35) 
No  (12/51) 
92.5 
87.6 
82.5-100 
78.2-96.9 
0.572 Yes (4/37) 
No  (11/48) 
  97.0 
  83.6 
91.1-100
72.4-94.8
0.289 Yes (12/72) 
No  (4/16) 
93.4 
74.0 
87.2-99.7 
52.1-96.0 
0.024 
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Table 4. Survival analyses in cohort B. 
 
 
A. PFS 
TP53 1p/19q MGMT IDH1  
P
a
t
i
e
n
t
s
 
(
n
)
 
E
v
e
n
t
s
 
(
n
)
 
 
Median 
PFS 
(95% CI) 
TP53 
mutation 
Median
PFS 
(years)
95% CI P value 
1p/19q 
loss 
Median 
PFS 
(years) 
95% CI P value 
MGMT 
promoter 
methylation 
Median 
PFS 
(years) 
95% CI P value
IDH1 
mutation 
Median 
PFS 
(years) 
95% CI P value 
A-II 38 19 5.1 
(1.8-8.4) 
Yes (3/6) 
No (11/18) 
5.1 
3.1 
0.7-9.4
0.2-5.9
0.682 Yes (1/8) 
No (15/27) 
- 
3.1 
- 
0.9-5.2
0.177 Yes (6/15) 
No (10/15) 
6.7 
1.3 
- 
- 
0.111 Yes (4/14) 
No (10/10) 
6.7 
1.0 
- 
0.3-1.7 
0.001 
OA-II and 
O-II 
12 3 12.4 
(-) 
Yes (0/1) 
No (2/8) 
- 
- 
- 
- 
- Yes (2/8) 
No (1/4) 
6.1 
- 
- 
- 
0.577 
- 
Yes (3/7) 
No (0/3) 
- 
- 
- 
- 
- 
- 
Yes (1/6) 
No (2/4) 
- 
- 
- 
- 
- 
- 
All tumors 50 22 6.1 
(2.1-10.1) 
Yes (3/7) 
No (13/26) 
5.1 
6.4 
0.8-9.3
0.5-12.2
0.907 Yes (3/16) 
No (16/31) 
6.1 
3.1 
0.0-
13.9 
0.6-5.6
0.018 Yes (9/22) 
No (10/18) 
6.1 
1.9 
0.7-11.5
0.0-4.5 
0.079 Yes (5/20) 
No (12/14) 
6.7 
1.2 
1.6-11.7 
0.0-2.4 
0.001 
B. OS 
TP53 1p/19q MGMT IDH1  
P
a
t
i
e
n
t
s
 
(
n
)
 
E
v
e
n
t
s
 
(
n
)
 
5-year OS rate 
(%) 
(95% CI) 
TP53 
mutation 
5-year 
OS rate
(%) 
95% 
CI 
P 
value 
1p/19q 
loss 
5-year 
OS rate
(%) 
95% 
CI 
P 
value
MGMT 
promoter 
methylation 
5-year 
OS rate
(%) 
95% 
CI 
P 
value
IDH1 
mutation 
5-year 
OS rate 
(%) 
95% 
CI 
P 
Value 
A II 38 7 85.0 
72.5-97.4 
Yes (2/6) 
No  (4/18) 
83.3 
80.5 
60.2-100
- 
0.520 Yes (0/8) 
No  (6/27) 
100 
84.7 
- 
70.9-98.5 
0.278 Yes (3/15) 
No  (4/15) 
92.3 
70.0 
77.8-100
44.5-95.5
0.168 Yes (1/14) 
No  (5/10) 
100 
56.0 
- 
22.6-89.4 
0.054 
OA II and 
O II 
12 1 100 Yes (0/1) 
No  (0/8) 
100 
100 
- 
- 
- Yes (1/8) 
No  (0/4) 
100 
100 
- 
- 
- Yes (1/7) 
No  (0/3) 
100 
100 
- 
- 
- Yes (0/6) 
No  (1/4) 
100 
100 
- 
- 
- 
All tumors 50 8 88.7 
79.2-98.2 
Yes (2/7) 
No  (4/26) 
85.7 
86.7 
59.8-100
72.5-100
0.264 Yes (1/16) 
No  (6/31) 
50.0 
86.5 
0-100 
74.1-98.8 
0.043 Yes (4/22) 
No  (4/18) 
95.0 
74.7 
85.4-100
52.6-96.8
0.162 Yes (1/20) 
No  (6/14) 
50.0 
68.8 
0-100 
42.7-94.8 
0.034 
 
 
 
 
Table 5. Multivariate analyses of survival to first PD, from first PD and OS in 
cohort A. 
 
 
A. Time to first PD    
 RR 95% CI P value 
Age 
  <40 
  >40  
 
1 
1.0 
 
 
0.5 to 1.8 
 
 
0.891 
Resection 
  no total 
  total 
 
1 
0.7 
 
 
0.4 to 1.3 
 
 
0.298 
Molecular markers 
  IDH1 mutant and 1p/19q loss 
  IDH1 mutant and no 1p/19q loss 
  IDH1 wild-type 
 
1 
1.4 
2.1 
 
 
0.7 to 2.6 
0.9 to 4.8 
 
 
0.362 
0.067 
B. Time from first PD    
 RR 95% CI P value 
Age 
   <40 
   >40 
 
1 
2.5 
 
 
0.7 to 8.7 
 
 
0.155 
Therapy 
   no 
   yes 
 
1 
0.4 
 
 
0.1 to 1.8 
 
 
0.217 
Resection 
  no total 
 
1 
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  total 0.4 0.1 to 1.4 0.163 
Molecular markers 
  IDH1 mutant and 1p/19q loss 
  IDH1 mutant and no 1p/19q loss 
  IDH1 wild-type 
 
1 
1.4 
3.0 
 
 
0.3 to 6.3 
0.6 to 14.5 
 
 
0.694 
0.183 
C. OS    
 Relative Risk 95% CI P value 
Age 
   <40 
   >40 
 
1 
2.5 
 
 
0.7 to 8.5 
 
 
0.147 
Resection 
   no total 
   total 
 
1 
0.3 
 
 
0.1 to 1.2 
 
 
0.090 
Molecular markers 
  IDH1 mutant and 1p/19q loss 
  IDH1 mutant and no 1p/19q loss 
  IDH1 wild-type 
 
1 
1.4 
4.1 
 
 
0.3 to 6.3 
0.8 to 20.2 
 
 
0.648 
0.081 
 
 
Years
O
ve
ra
ll 
su
rv
iv
al
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A II
(n=40)
OA II
(n=23)
O II
(n=26)p=0.464
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Age ≤ 40
(n=54)
Age > 40
(n=35)p=0.032
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
no total resection
(n=43)
total resection
(n=38)p=0.036
A B C
 
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
TP53 wt 
(n=23)
TP53 mut 
(n=16)p=0.272
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
TP53 wt 
(n=40)
TP53 mut 
(n=8)p=0.702
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
TP53 wt 
(n=63)
TP53 mut 
(n=24)p=0.499
O
ve
ra
ll 
su
rv
iv
al
D E FA II OA II/O II all tumors
 
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
no Del 1p/19q
(n=32)
Del 1p/19q
(n=5)p=0.701
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
no Del 1p/19q
(n=19)
Del 1p/19q
(n=30)p=0.890
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
no Del 1p/19q
(n=51)
Del 1p/19q
(n=35)p=0.572
O
ve
ra
ll 
su
rv
iv
al
G H IA II OA II/O II all tumors
 
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
MGMT meth-
(n=27)
MGMT meth+
(n=11)
p=0.338
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
MGMT meth-
(n=21)
MGMT meth+
(n=26)p=0.788
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
MGMT meth-
(n=48)
MGMT meth+
(n=37)p=0.289
O
ve
ra
ll 
su
rv
iv
al
J K LA II OA II/O II all tumors
 
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
IDH1 wt
(n=10)
IDH1 mut
(n=29)p=0.071
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
IDH1 wt
(n=6)
IDH1 mut
(n=43)p=0.267
Years
0 2 4 6 8 10 12 14 16 18
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
IDH1 wt
(n=16)
IDH1 mut
(n=72)p=0.024
O
ve
ra
ll 
su
rv
iv
al
A II OA II/O II all tumorsM N O
 
Supplementary Table 1. Individual patient data indicating cohort, diagnosis, 
molecular markers, and overlap with previous publication in Clinical Cancer 
Research (7). 
 
 Cohort 
 
Histology 
 
p53 
mt 
1p/19q 
codel 
MGMT 
meth 
IDH 
mt 
Included in 
ref. 7 
1 A A II + - + + - 
2 A A II - - - + - 
 A A II + - - + - 
4 A A II + - + + - 
5 A A II - - - + - 
6 A A II - - n.a. + - 
7 A A II + - + + - 
8 A A II + - - + - 
9 A A II - n.a. + - - 
10 A A II - n.a. - + - 
11 A A II - - + - - 
12 A A II - - - + + 
13 A A II n.a. - n.a. n.a. - 
14 A A II + - - + - 
15 A A II - + - + - 
16 A A II - - - + - 
17 A A II - + + + - 
18 A A II - - - - - 
19 A A II - - - + - 
20 A A II - - - + - 
21 A A II - - - + - 
22 A A II + - - + - 
23 A A II + - - + - 
24 A A II + - + - - 
25 A A II - + - - - 
26 A A II - - - - - 
27 A A II - + + - - 
28 A A II - - - - - 
29 A A II - + + + - 
30 A A II + - - + - 
31 A A II + n.a. - + - 
32 A A II + - - + - 
33 A A II - - + + - 
34 A A II + - + + - 
35 A A II + - - + - 
36 A A II + - - + - 
37 A A II - - - - - 
38 A A II + - - + - 
39 A A II - - - + - 
40 A A II - - - - - 
41 A OA II - - + - + 
42 A OA II + + + + + 
43 A OA II - + + + + 
44 A OA II - + - + + 
45 A OA II - - - - + 
46 A OA II - + + + + 
47 A OA II - + + + + 
48 A OA II - + + + + 
49 A OA II + - + + + 
50 A OA II + - - + + 
51 A OA II + - + + + 
52 A OA II - - + + + 
53 A OA II - + - + + 
54 A OA II - - + + + 
55 A OA II - + - + + 
56 A OA II - + + - + 
57 A OA II - - + + + 
58 A OA II - + + + + 
59 A OA II + - - + + 
60 A OA II - + n.a. + + 
61 A OA II - - - + + 
62 A OA II - - - - + 
63 A OA II - + + + + 
64 A O II - + - + + 
65 A O II - + + + + 
66 A O II - + + + + 
67 A O II + - - + + 
68 A O II n.a. - + + + 
69 A O II - + - + + 
70 A O II - + - - + 
71 A O II + - - + + 
72 A O II + - - + + 
73 A O II - + + + + 
74 A O II - + n.a. + + 
75 A O II - + - + + 
76 A O II - + + + + 
77 A O II - + - - + 
78 A O II - + - + + 
79 A O II - + - + + 
80 A O II - + + + + 
81 A O II - - - + + 
 2
82 A O II - + + + + 
83 A O II - + + + + 
84 A O II - - + + + 
85 A O II - + + + + 
86 A O II - - + + + 
87 A O II - + - + + 
88 A O II - + - + + 
89 A O II - - + + + 
90 B A II + - n.a. + - 
91 B A II + - - - - 
92 B A II - - - + - 
93 B A II - - - - - 
94 B A II - - - + - 
95 B A II + - + - - 
96 B A II - - + + - 
97 B A II n.a. - n.a. n.a. - 
98 B A II - - + + - 
99 B A II - - + + - 
100 B A II - + - + - 
101 B A II + - + + - 
102 B A II - - - + - 
103 B A II - + + + - 
104 B A II + - - - - 
105 B A II - + - + - 
106 B A II - + + + - 
107 B A II - n.a. n.a. - - 
108 B A II - - - - - 
109 B A II - - - - - 
110 B A II - n.a. - - - 
111 B A II - - - - - 
112 B A II n.a. - n.a. n.a. - 
113 B A II n.a. + n.a. n.a. - 
114 B A II n.a. + n.a. n.a. - 
115 B A II n.a. - + n.a. - 
116 B A II n.a. - + n.a. - 
117 B A II - - - + - 
118 B A II n.a. - + n.a. - 
119 B A II n.a. + + n.a. - 
120 B A II n.a. - + n.a. - 
121 B A II n.a. - n.a. n.a. - 
122 B A II + - - + - 
123 B A II n.a. + + n.a. - 
124 B A II n.a. - + n.a. - 
125 B A II - - - - - 
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126 B A II n.a. n.a. + n.a. - 
127 B A II n.a. - n.a. n.a. - 
128 B OA II n.a. - n.a. n.a. - 
129 B OA II - + + + - 
130 B OA II - + + + - 
131 B OA II - + + + + 
132 B OA II n.a. - n.a. n.a. - 
133 B OA II - - + - - 
134 B OA II - + - - + 
135 B O II - + - + - 
136 B O II + - - + - 
137 B O II n.a. + + - + 
138 B O II - + + + - 
139 B O II - + + - - 
Supplementary Table 2. Molecular markers by age, gender, histology and extent of resection in cohort B 
 
 All TP53 mutation 
no TP53 
mutation 
P 
value 
1p/19q 
loss 
no 
1p/19q 
loss 
P 
value 
MGMT 
promoter 
methylati
on 
no 
MGMT 
promoter 
methylati
on 
P 
value 
IDH1 
mutation 
no 
IDH1 
mutation 
P 
value 
Age (Years)    0.279   0.615   0.154   0.008 
< 40 
 
> 40 
 
 
 
 
Median 
(Range) 
20 
(40.0%) 
30 
(60.0%) 
 
50 (100%) 
 
43.0 
(18.3-74.7) 
4 
(57.1%) 
3 
(42.9%) 
 
7 (100%) 
 
39.7 
(26.1-65.5) 
9 
(34.6%) 
17 
(65.4%) 
 
26 (100%) 
 
46.2 
(27.5-70.4) 
 6 
(37.5%) 
10 
(62.5%) 
 
16 (100%) 
 
42.4 
(27.9-62.7) 
14 
(45.2%) 
17 
(54.8%) 
 
31 (100%) 
 
42.2 
(18.3-74.7) 
 11 
(50.0%) 
11 
(50.0%) 
 
22 (100%) 
 
40.4 
(22.9-74.7) 
5 
(27.8%) 
13 
(72.2%) 
 
18 (100%) 
 
46.2 
(33.1-70.4) 
 12 
(60.0%) 
8 
(40.0%) 
 
20 (100%) 
 
39.1 
(27.5-63.6) 
2 
(14.3%) 
12 
(85.7%) 
 
14 (100%) 
 
53.5 
(26.1-70.4) 
 
Gender    0.661   0.541   0.510   1.000 
Male 29 
(58.0%) 
4 
(57.1%) 
18 
(69.2%) 
 8 
(50.0%) 
19 
(61.3%) 
 13 
(59.1%) 
13 
(72.2%) 
 13 
(65.0%) 
10 
(71.4%) 
 
Female 21 
(42.0%) 
 
3 
(42.9%) 
8 
(30.8%) 
 8 
(50.0%) 
12 
(38.7%) 
 9 
(40.9%) 
5 
(27.8%) 
 7 
(35.0%) 
4 
(28.6%) 
 
 50 (100%) 7 (100%) 26 (100%)  16 (100%) 31 (100%)  22 (100%) 18 (100%)  20 (100%) 14 (100%)  
Histological 
diagnosis 
   0.642   0.012   0.464   1.000 
A II 38 
(76.0%) 
6 
(85.7%) 
18 
(69.2%) 
 8 
(50.0%) 
27 
(87.1%) 
 15 
(68.2%) 
15 
(83.3%) 
 14 
(70.0%) 
10 
(71.4%) 
 
OA II/O II 12 
(24.0%) 
 
1 
(14.3%) 
8 
(30.8%) 
 8 
(50.0%) 
4 
(12.9%) 
 7 
(31.8%) 
3 
(16.7%) 
 6 
(30.0%) 
4 
(28.6%) 
 
 50 (100%) 7 (100%) 26 (100%)  16 (100%) 31 (100%)  22 (100%) 18 (100%)  20 (100%) 14 (100%)  
 6
Extent of 
resection 
   0.063*   0.002*   0.405*   1.000* 
Biopsy only 28 
(56.0%) 
1 
(16.7%) 
13 
(50.0%) 
 7 
(43.8%) 
20 
(64.5%) 
 12 
(54.5%) 
8 
(47.1%) 
 8 
(42.1%) 
6 
(42.9%) 
 
Partial 
(<50%) 
9 
(18.0%) 
4 
(66.7%) 
3 
(11.5%) 
 0 
(0.0%) 
8 
(25.8%) 
 2 
(9.1%) 
5 
(29.4%) 
 3 
(15.8%) 
4 
(28.6%) 
 
Subtotal 
(50-99%) 
7 
(14.0%) 
1 
(16.7%) 
6 
(23.1%) 
 5 
(31.3%) 
2 
(6.5%) 
 4 
(18.2%) 
3 
(17.6%) 
 5 
(26.3%) 
2 
(14.3%) 
 
Total 5 
(10.0%) 
0 
(0.0%) 
4 
(15.4%) 
 4 
(25.0%) 
1 
(3.2%) 
 4 
(18.2%) 
1 
(5.9%) 
 3 
(15.8%) 
2 
(14.3%) 
 
Not available 1 
(2.0%) 
            
 50 (100%) 6 (100%) 26 (100%)  16 (100%) 30 (100%)  22 (100%) 17 (100%)  19 (100%) 14 (100%)  
 
Abbreviations: A II astrocytoma, OA II oligoastrocytoma, O II, oligodendroglioma; * p-values were calculated based on evaluable cases 
 
Supplementary Table 3. Patterns of molecular changes in cohort A+B WHO 
grade II gliomas by astrocytic versus oligodendroglial histology. 
 
Diagnosis  
A II OA II/O II
All 
tumors 
10 2 12 No molecular marker altered 
17.9% 3.6% 10.8% 
12 2 14 --------- / IDH1 / ------- / --------- 
21.4% 3.6% 12.6% 
2 0 2 --------- / ------- / TP53 / ---------  
3.6% 0% 1.8% 
11 6 17 --------- / IDH1 / TP53 / --------- 
19.6% 10.9% 15.3% 
1 2 3 --------- / ------- / ------- / MGMT  
1.8% 3.6% 2.7% 
4 6 10 --------- / IDH1 / ------- / MGMT  
7.1% 10.9% 9.0% 
2 0 2 --------- / ------- / TP53 / MGMT  
3.6% 0% 1.8% 
5 2 7 --------- / IDH1 / TP53 / MGMT 
8.9% 3.6% 6.3% 
1 3 4  1p/19q / ------  / ------- / ---------  
1.8% 5.5% 3.6% 
3 11 14 1p/19q / IDH1 / ------- / --------- 
5.4% 20.0% 12.6% 
1 2 3  1p/19q / ------- / ------- / MGMT 
1.8% 3.6% 2.7% 
4 18 22 1p/19q / IDH1 / ------- / MGMT 
7.1% 32.7% 19.8% 
0 1 1 1p/19q / IDH1 / TP53 / MGMT 
0% 1.8% 0.9% 
56 55 111 All tumors 
100.0% 100.0% 100.0% 
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Supplementary Table 4. Multivariate analyses of PFS in cohort B. 
 
 
PFS    
 RR 95% CI P value 
Age 
  <40 
  >40  
 
1 
1.4 
 
 
0.3 to 7.2 
 
 
0.671 
Resection 
  no total 
  total 
 
1 
0.7 
 
 
0.1 to 5.5 
 
 
0.729 
Molecular markers 
  IDH1 mutant and 1p/19q loss 
  IDH1 mutant and no 1p/19q loss 
  IDH1 wild-type 
 
1 
2.5 
10.8 
 
 
0.2 to 29.8 
1.2 to 100.3 
 
 
0.457 
0.037 
 
 
 
